MEI Pharma, Inc (MEIP)

Etorro trading 970x250
MEI Pharma, Inc (MEIP) Logo

About MEI Pharma, Inc

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California. Address: 11455 El Camino Real, San Diego, CA, United States, 92130

MEI Pharma, Inc News and around…

Latest news about MEI Pharma, Inc (MEIP) common stock and company :

MEI Pharma, Inc. (NASDAQ:MEIP) Is Expected To Breakeven In The Near Future
22 Oct, 2021 Yahoo! Finance

MEI Pharma, Inc. ( NASDAQ:MEIP ) is possibly approaching a major achievement in its business, so we would like to shine...

40 Biggest Movers From Yesterday
07 Oct, 2021 FinancialContent

Gainers Volcon, Inc. (NASDAQ: VLCN) shares jumped 97.5% to settle at $10.86 on Wednesday as the company priced its IPO at $5.50 ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
06 Oct, 2021 FinancialContent

Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular ...

2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10
06 Oct, 2021 Yahoo! Finance

Out on Wall Street, one group of stocks divides investors into either fans or critics. Penny stocks, or tickers that trade for less than $5 per share, are known for stirring up mixed reactions among market watchers, as these names are unrivaled in terms of both their risk and reward potential. Some argue the bargain prices are just too good to be true, noting that there could be a very legitimate reason they are trading at such low levels. Problems like weak fundamentals or overwhelming headwind

MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Oct, 2021 FinancialContent

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 136,000 shares of the company’s common stock to three new employees. The stock options were granted as a material inducement to each new employee accepting employment with MEI in accordance with Nasdaq Listing Rule 5635(c)(4).

MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
22 Sep, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present a company overview and business update at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 4:00 p.m. Eastern Time.

Companies Like MEI Pharma (NASDAQ:MEIP) Are In A Position To Invest In Growth
07 Sep, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

MEI Pharma, Inc. (MEIP) Reports Break-Even Earnings for Q4
02 Sep, 2021 Yahoo! Finance

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 100.00% and 95.18%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights
02 Sep, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2021.

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
02 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

MEI Pharma to Present at Two Healthcare Conferences
02 Sep, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present a company overview and business update at two upcoming investor conferences:

Earnings Scheduled For September 2, 2021
02 Sep, 2021 FinancialContent

Companies Reporting Before The Bell • Navios Maritime Holdings (NYSE:NM) is projected to report earnings for its ...

How The Parts Add Up: VTWG Headed For $268
01 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $267.60 per unit.

MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021
26 Aug, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2021 fiscal year end financial results after the close of the U.S. financial markets on September 2, 2021. The Company will host a conference call and live webcast with the investment community to provide a corporate overview and update the same day at 5:00 p.m. ET.

Mei (MEIP) Begins Phase III Study for B-Cell Malignancies
18 Aug, 2021 Yahoo! Finance

Mei Pharma (MEIP) doses first patient in phase III study to evaluate zandelisib plus rituximab in follicular lymphoma or marginal zone lymphoma.

MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma
17 Aug, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced the dosing of the first patient in a Phase 3 study of zandelisib known as COASTAL. COASTAL is evaluating zandelisib, a selective phosphatidylinositol 3-kinase delta ("PI3Kδ")

MEI Pharma Announces Planned Chief Financial Officer Transition
05 Aug, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Brian Drazba, chief financial officer of MEI Pharma, has informed the company that he is retiring. Mr. Drazba, an industry veteran who has overseen financial operations since joining in April 2017, will continue to serve in his current role and provide transitional support through the end of 2021.

MEI Pharma Inc (MEIP): Are Hedge Funds Right About This Stock?
29 Jul, 2021 Yahoo! Finance

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 866 world-class investment firms that we track and now have access to the collective wisdom contained in […]

What You Need To Know About MEI Pharma, Inc.'s (NASDAQ:MEIP) Investor Composition
16 Jul, 2021 Yahoo! Finance

A look at the shareholders of MEI Pharma, Inc. ( NASDAQ:MEIP ) can tell us which group is most powerful. Institutions...

MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer
07 Jul, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Tina C. Beamon, J.D., as chief compliance officer, effective immediately. Ms. Beamon will be responsible for the enterprise-wide compliance programs that manage risks associated with core business activities.

Sum Up The Pieces: OMFS Could Be Worth $47
28 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $46.95 per unit.

First Week of July 16th Options Trading For MEI Pharma (MEIP)
15 Jun, 2021 FinancialContent

Investors in MEI Pharma Inc (MEIP) saw new options begin trading this week, for the July 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MEIP options chain for the new July 16th contracts and identified the following call contract of particular interest.

Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts
13 Jun, 2021 FinancialContent
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
09 Jun, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta ("PI3K") inhibitor in clinical development for the treatment of B-cell maligna

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
07 Jun, 2021 FinancialContent

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical ...

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib
07 Jun, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced the dosing of the first patient with relapsed or refractory marginal zone lymphoma enrolled in the recently added second arm of the global Phase 2 TIDAL study of zandelisib,

MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting
04 Jun, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will host an investor and analyst video webcast event on Thursday, June 10, 2021 at 12:00 PM ET following the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The event will include a review of the zandelisib program, including recent data presented at ASCO, and commentary from key opinion leader Deepa Jagadeesh, M.D., MPH, a board-certified medi

MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
19 May, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced new data for zandelisib, an investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor in clinical development for the treatment of B-cell malignancies. The research and the design of a Phase 3 study will be presented in three posters at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021 being held virtually June 4-8, 2021.

77 Biggest Movers From Yesterday
14 May, 2021 FinancialContent

Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped ...

MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
12 May, 2021 Yahoo! Finance

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced updated clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor in clinical development for the treatment of B-cell malignancies, in combination with zanubrutinib (marketed as BRUKINSA®), an inhibitor of Bruton's tyrosine kinase developed by BeiGene, Ltd., in patients with relapsed or refractory B-cell malignancies, will be highlighted in an oral presentation at the European Hematology Association (EHA) 2021 Virtual Congress to be held June 9 – 17, 2021.

MEI Pharma, Inc (MEIP) is a NASDAQ Common Stock listed in , ,

970x250